-
- 1800 2010
- EN
-1366x0.jpg)
News
Array
(
[0] => stdClass Object
(
[id] => 1155
[id_crawler] =>
[category_product] => NULL
[thumbnail] => z4872548375944_b791d276bb7baab188658c90466b6101.jpg
[album] =>
[url_video] =>
[is_status] => 1
[is_featured] => 0
[is_form] => 1
[displayed_time] => 2023-11-13
[program] => 0
[number] => 1
[viewed] => 0
[type] =>
[type_career] =>
[level] =>
[address] =>
[address_career] =>
[expiration_time] => 0000-00-00
[created_time] => 2023-11-14 10:20:10
[updated_time] => 2024-08-28 13:39:14
[files] =>
[salary] =>
[time] =>
[created_by] => 63
[is_table_content] => 1
[language_code] => en
[slug] => GENTIS-sponsors-and-presented-at-the-colloquium-on-preimplantation-genetic-testing
[title] => GENTIS Sponsored and Presented at the Colloquium on Preimplantation Genetic Testing
[description] => On November 11, 2023, Ho Chi Minh City Society for Reproductive Medicine (HOSREM) organized a colloquium on Preimplantation Genetic Testing at the Caravelle Saigon Hotel. GENTIS was honored to be the main sponsor and to participate in presenting at the event, contributing to its overall success.
[content] => The workshop was attended by leading experts, including Ho Manh Tuong MD., MSc, Head of the Assisted Reproduction Unit at My Duc Hospital and Secretary-General of Ho Chi Minh City Society for Reproductive Medicine, Prof. Nguyen Dinh Tao, PhD, President of the Assisted Reproduction Society, etc. And more than 200 delegates, including leading professors, obstetricians, embryologists, and leaders of assisted reproduction centers from leading hospitals, medical facilities, and testing centers nationwide, also participated.
The colloquium on Preimplantation Genetic Testing is a prestigious scientific event highly regarded by the medical community in the field of assisted reproduction. It is a reliable forum for experts, doctors, embryologists, and healthcare professionals to exchange, share, and learn from each other.
The workshop was divided into four sessions, with a total of 22 research papers presented in the plenary session and one poster presentation by leading experts nationwide. The presenters focused on discussing preimplantation genetic testing (PGT).
Opening Session I, Doan Thi Hang, MD, PhD, Deputy Director of Military Institution of Clinical Embryology and Histology, presented a paper on "The history of PGT development in Vietnam." In her presentation, Dr. Hang clearly outlined the history of PGT development worldwide and in Vietnam. The presentation pointed out that GENTIS was the first unit to introduce PGT to Vietnam by importing the first Illumina NGS system in 2013. By 2015, PGT was officially applied in Vietnam.
In 2023, GENTIS became the first unit in Vietnam to achieve ISO 15189:2012 for PGT-A testing services. With the development and advancement of science and technology, strategies for analyzing the genetic material of embryos are constantly being improved, thereby enhancing the quality of testing and the effectiveness of PGT in Assisted Reproduction.
Dr. Doan Thi Hang, Deputy Director of Military Institution of Clinical Embryology and Histology, presented a report on "The history of PGT development in Vietnam."
To ensure the quality of PGT testing, technical factors and technology are of paramount importance. This information was presented by Nguyen Quang Vinh, MSc, Director of the GENTIS Testing Center, in his report titled "Technical factors and technology in controlling and improving the quality of PGT testing."
Mr. Vinh stated that GENTIS is currently using Next-Generation Sequencing (NGS) technology from Illumina (USA) for PGT testing. The outstanding advantage is that it has been proven to have 100% accuracy compared to the aCGH method and detects mosaicism more effectively than aCGH (from 20% to 80%). Additionally, it offers higher resolution in detecting chromosomal structures compared to aCGH (detecting chromosomal deletions of up to 5 Mb; currently, it has been optimized to detect two more microdeletions of 2 Mb in size: 22q11 and 1p36).
Nguyen Quang Vinh, MSc, Director of the Testing Center, presented a report on "Technical factors and technology in controlling and improving the quality of PGT testing".
Additionally, the PGT laboratory must adhere to the ESHRE guidelines for PGT laboratory requirements, with a particular focus on sample transportation from the IVF center. Furthermore, the PGT laboratory must participate in the annual external quality assessment program of GENQA and obtain ISO 15189:2012 certification. All of these requirements are fully complied with and implemented by GENTIS to control and enhance the quality of PGT testing
Assoc. Prof. Ho Sy Hung, PhD from Hanoi Medical University presented a report on "The application of PGT testing in the detection and screening of diseases in preimplantation embryos in Vietnam".
According to experts, PGT testing can be applied to detect and screen diseases in preimplantation embryos. This has been clearly presented by Assoc. Prof. Ho Sy Hung, PhD in his report. Dr. Hung stated that in Vietnam, PGT tests for screening genetic diseases such as PGT-M and PGT Max 1 are being increasingly optimized in terms of time and cost, giving more families with genetic diseases the opportunity to access this technology.
Specialist level 1 doctor Nguyen Van Thong from Hung Vuong Hospital presented a paper on "Genetic counseling for transferring mosaic embryos."
The topic of counseling for transferring mosaic embryos, presented by Specialist level 1 doctor Thong, also attracted significant attention from the delegates. Dr. Thong suggested that counseling for mosaic embryos should prioritize factors such as the percentage of mosaicism in the biopsy sample, the number of chromosomes involved: 1 or more chromosomes, the type of chromosomes, complete or partial chromosome mosaicism, Monosomy or Trisomy type. Additionally, healthcare providers should provide multidisciplinary counseling and follow-up for embryos with mosaicism.
Furthermore, the conference featured numerous other scientific presentations, including
- “Choosing ICSI or IVF fertilization methods for PGT cases" by Nguyen Thi Cam Van, MD, MSc from Vinmec International General Hospital.
- "The efficacy of preimplantation genetic testing for aneuploidy (PGT-A) in patients with poor ovarian response” - M.S. Ho Thi My Trang at My Duc Phu Nhuan Hospital.
- “The future of preimplantation genetic screening for embryos at risk of gynecological cancer gene mutations: Potential and challenges.” - Nguyen Hai Phuong, MD, MSc at National hospital of Obstetrics and Gynecology.
These presentations provided healthcare professionals with updated knowledge about PGT and offered new perspectives on this testing method, enabling them to better support infertile couples.
As a pioneer in introducing PGT to Vietnam and a global partner of major companies like Illumina (USA), Qiagen, Sigma, etc, GENTIS has played a significant role in helping couples select genetically healthy embryos, increasing the success rates of IVF and ensuring the birth of healthy babies, not affected by any genetic syndromes detected through screening
GENTIS's PGT tests have become widely adopted by IVF centers nationwide, including:
- PGT-A/SR: DNA analysis to detect abnormalities in the number (aneuploidy) of all 24 pairs of chromosomes and structural abnormalities of chromosomes in embryos.
- PGTest-M: diagnose single-gene genetic disorders.
- PGT-Max 1: an advanced genetic test that uses groundbreaking technology to detect smaller structural abnormalities in chromosomes, specifically microdeletion/microduplication greater than 2 Mb in size, associated with a number of common genetic diseases and syndromes.
- ASEM test: a genetic analysis of the embryo culture environment.
Through this colloquium on Preimplantation Genetic Testing, GENTIS aims to strengthen its partnership with leading medical institutions across the country, providing a comprehensive testing ecosystem to better serve the healthcare needs of Vietnamese people. By doing so, GENTIS is realizing its vision of bringing happiness to infertile families.
[content_more] => [meta_title] => GENTIS Sponsored and Presented at the Colloquium on Preimplantation Genetic Testing [meta_description] => GENTIS was honored to be the main sponsor and to participate in presenting at the event, contributing to its overall success [meta_keyword] => Gentis,mainsponsor,presented,event [thumbnail_alt] => [post_id] => 1155 [category_id] => 4 ) [1] => stdClass Object ( [id] => 1152 [id_crawler] => [category_product] => NULL [thumbnail] => hội-thảo-pgt-ngang.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 1 [displayed_time] => 2023-11-07 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2023-11-07 14:50:27 [updated_time] => 2024-08-28 13:31:37 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => GENTIS-Proudly-Sponsors-Pre-implantation-Genetic-Testing-Symposium [title] => GENTIS Proudly Sponsors Pre-implantation Genetic Testing Symposium [description] => The Pre-implantation Genetic Testing Symposium will be held at 8 AM on Saturday, November 11, 2023, at Caravelle Saigon Hotel. [content] =>Organized by Hosrem, the symposium has attracted the attention of numerous experts, doctors, researchers, and embryologists. This event provides an opportunity for professionals in the field of assisted reproduction to exchange knowledge and enhance their expertise.
GENTIS is honored to be the main sponsor of the Pre-implantation Genetic Testing Symposium. As part of our participation, we will be hosting an informative booth showcasing our advanced PGT testing services. Additionally, we will be conducting engaging mini-games with exciting prizes for all attending physicians.
Our esteemed colleague, Mr. Nguyen Quang Vinh, Head of Medical Laboratory Center, will be delivering a keynote speech entitled "Technical and Technological Factors in Quality Control and Improvement of PGT Testing".
We cordially invite all physicians to join us!
[content_more] => [meta_title] => GENTIS Proudly Sponsors Pre-implantation Genetic Testing Symposium [meta_description] => The Pre-implantation Genetic Testing Symposium will be held at 8 AM on Saturday, November 11, 2023, at Caravelle Saigon Hotel. [meta_keyword] => GeneticTesting,Gentis,Sponsors,Symposium [thumbnail_alt] => [post_id] => 1152 [category_id] => 4 ) [2] => stdClass Object ( [id] => 1151 [id_crawler] => [category_product] => NULL [thumbnail] => ht-sk_2023/thue_thủ_đo_2023/286936ed7411a34ffa00.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2023-10-27 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2023-10-27 16:42:14 [updated_time] => 2024-08-28 13:27:23 [files] => [salary] => [time] => [created_by] => 62 [is_table_content] => 0 [language_code] => en [slug] => GENTIS-was-recognized-as-an-exemplary-taxpaying-business-in-the-Capital-City-for-2022 [title] => GENTIS was recognized as an exemplary taxpaying business in the Capital City for 2022. [description] => On the morning of October 26th, the Hanoi Tax Department convened the "Commendation of Exemplary Taxpayers in the Capital City for 2022" conference. GENTIS was honored as one of the outstanding taxpaying enterprises that made substantial contributions to the national and social budget over the year of 2022. [content] =>
The "Commendation of Exemplary Taxpayers in the Capital City" conference aimed to recognize the contributions of enterprises and entrepreneurs. It also served to encourage and inspire the business community to continue overcoming challenges and developing their production and business operations. The conference was attended by Mr. Ha Minh Hai - Hanoi Deputy Mayor, Mr. Vu Manh Cuong - Director of Hanoi Tax Department, Mr. Mai Son - Deputy General Director of General Department of Taxation Mai Son, representatives from government agencies, media outlets, and participating enterprises.
At the event, GENTIS was honored to receive a Certificate of Merit from the Hanoi Deputy Mayor. Since its establishment, GENTIS has consistently complied with and implemented tax policies and laws, fulfilling its tax obligations to the national budget. GENTIS not only contributes a significant amount to the national budget, but also plays a leading and critical role in ensuring income and social security for its employees, thereby contributing to the socioeconomic development of the capital city in particular and the country in general.
Mr. Do Manh Ha, General Director of GENTIS, expressed his gratitude and pride at the commendation ceremony: "Contributing to the community is the responsibility of every enterprise. GENTIS is honored to be recognized by the Hanoi Tax Department for our positive contributions to the country. We commit to continuing to contribute to the economic development and social welfare of the capital city in particular and the country in general. GENTIS will continue to maintain the highest standards in all of our activities, including strict compliance with tax policies and laws, as well as transparency in our business operations."
Tax payment is not only an obligation, but also a crucial stepping stone that helps the country build a strong financial foundation to advance its development and take a leading position in the Southeast Asian region. Above all, GENTIS aspires to become a brand that is endorsed by the country, affirming its mission and stature on the journey to enhance the physical and intellectual well-being of the Vietnamese people.
[content_more] => [meta_title] => GENTIS was recognized as an exemplary taxpaying business in the Capital City for 2022. [meta_description] => On the morning of October 26th, the Hanoi Tax Department convened the "Commendation of Exemplary Taxpayers in the Capital City for 2022" [meta_keyword] => Gentis,Recognized,Business [thumbnail_alt] => [post_id] => 1151 [category_id] => 4 ) [3] => stdClass Object ( [id] => 1150 [id_crawler] => [category_product] => NULL [thumbnail] => ht-sk_2023/sinh_nhật_gentis_2023/gentis_95.png [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 0000-00-00 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2023-10-27 15:53:27 [updated_time] => 2024-08-20 08:43:31 [files] => [salary] => [time] => [created_by] => 62 [is_table_content] => 0 [language_code] => en [slug] => gentis-commemorated-13-years-of-establishment-promoting-the-spirit-of- union-for-breakthrough [title] => GENTIS commemorated 13 Years of Establishment: Promoting the Spirit of UNION FOR BREAKTHROUGH [description] => On October 25-26, 2023, GENTIS organized a commemoration to mark the 13th anniversary of the company's establishment (October 26, 2010 - October 26, 2023) in the coastal city of Ha Long. The anniversary program served as GENTIS' sincere expression of gratitude to the Valued Partners, Valued Customers, and all of its employees. [content] =>
The 13-year journey (October 26, 2010 - October 26, 2023), driven by the mission of "Enhancing the physical and intellectual well-being of Vietnamese people", has propelled GENTIS to become a reputable brand in Vietnam in particular and in Asia in general, in the field of genetic analysis and molecular biology.
With the spirit of "Union for Breakthrough" - on the occasion of its 13th anniversary, GENTIS organized a meaningful 2-day, 1-night trip to the city of Ha Long, aimed at strengthening the unity and collective strength of the entire company.
The program started with a series of team building challenges along the sunny and blustery shores of Ha Long Bay. Despite the scorching sun drenching their shirts in sweat and the sand underfoot making every step arduous, the GENTIS employees remained resolute and united in their collective determination to conquer each challenge.
The GENTIS's valiant warrior “aimed and hit the target”
Undaunted by challenges, they resolutely reached the finish line.
With unity of mind and collective effort, they overcame every challenge standing in their path.
With the steed by their side, they feared no arduousness
Together, GENTIS employees successfully conquered every difficulty and challenge
The 13th anniversary celebration gala of GENTIS was held with great solemnity at the Saigon Ha Long Hotel, having the honor of welcoming esteemed guests: Ms. Ngo Thi Xuan Dung - Member of the Board of Directors, Mr. Ngo Ba Binh - Member of the Board of Directors, and Mr. Do Manh Ha - General Director of the company. GENTIS was also delighted to welcome the valued dealers, trusted partners, and the entire GENTIS workforce presenting at the event.
The anniversary gala had the attendance of the Board of Directors and the Company's Executive Leadership.
In his speech at the event, Mr. Do Manh Ha - the Company's General Director, expressed his hope that GENTIS will continue to grow and mature, with an increasing number of members, better achievements, and even stronger bonds among them. The General Director also conveyed his deep gratitude to the Valued Partners and Customers who have always supported GENTIS. He also extended a sincere appreciation to the entire GENTIS workforce, from the members who have been with the company since its founding to the new joiners.
Mr. Do Manh Ha - the General Director of GENTIS, delivered a speech at the program.
At the Gala evening, GENTIS enthusiastically honored the long-serving employees who have accompanied the development of the company. These are the members who have worked at GENTIS for 5 years, 10 years, and are certainly set to continue for many more years in the future.
The solemn moment of honoring the GENTIS employees who have dedicated 10 years and 5 years of service to the company.
Let’s take a look at the impressive images of GENTIS from its 13th-anniversary gala celebration:
What is Preeclampsia?
Preeclampsia is a multi-organ syndrome that develops in the latter half of pregnancy, classically defined by the presence of hypertension accompanied by proteinuria or multi-organ dysfunction.
- Hypertension in pregnancy is defined as the elevation of blood pressure after 20 weeks of gestation, measured on at least two occasions spaced at least 4 hours apart. In cases of pre-existing chronic hypertension where the following additional factors emerge, the condition is classified as superimposed preeclampsia on chronic hypertension.
- The key signs and symptoms used to diagnose preeclampsia include:
- Proteinuria: ≥300 mg protein on 24-hour urine collection, or Protein/creatinine ratio ≥30 mg/mmol
- Renal impairment: Serum creatinine ≥90 μmol/L
- Hepatic dysfunction: Liver enzyme levels elevated 2x above the normal range, or having abnormal upper quadrant pains
- Neurological complications: Eclampsia, stroke, altered mental status, severe headaches, visual disturbances, temporary blindness
- Hematological complications: Thrombocytopenia (<150,000/dL), Disseminated intravascular coagulation, or Hemorrhage
Who is having a high risk of preeclampsia?
According to the recommendations of the American College of Obstetricians and Gynecologists (ACOG), the following groups are identified as high-risk populations and should receive preventive treatment:
- Primigravida
- Multifetal pregnancy (twins, triplets, etc.)
- Having a history of preeclampsia in the previous pregnancy
- Systemic lupus erythematosus (SLE)
- Hemophilia
- Chronic hypertension - Hemophilia
- Pre-pregnancy body mass index (BMI) over 35 kg/m2
- Antiphospholipid syndrome
- Diabetes mellitus or gestational diabetes
- Maternal age over 35 years
- Renal disorders
- Obstructive sleep apnea
- Using assisted reproductive technologies
However, if we only follow the recommendations of ACOG, doing so could result in failing to identify and treat up to 50% of the individuals who require medical intervention.
The biological mechanism of Preeclampsia
When the embryo implants into the uterus and creates the fetus and the placenta, the trophoblast cells of the placenta then invade the spiral arteries of the mother’s uterus, and new blood vessels form to ensure a sufficient blood supply to the placenta.
In the case of women with preeclampsia, the development of these vascular structures appears to be inadequate. The placenta releases various substances into the maternal spiral arteries, including two distinct factors:
- PIGF: A pro-angiogenic factor that promotes vascular growth, facilitating improved placental development and enhanced nutrient delivery from the mother to the fetus.
- sFlt1: An anti-angiogenic factor that helps to prevent the vascular system from becoming excessive and overtaking the maternal organism, ensuring fetal development does not compromise the mother's well-being.
The ratio between the sFlt1 and PIGF factors fluctuates throughout the course of gestation. When this ratio is balanced, it helps the fetus develop without adversely impacting maternal health (this balance is not a 1:1 ratio, but rather varies across different populations and ethnicities).
When the placenta experiences inadequate perfusion, the trophoblast cells fail to adequately invade the maternal spiral arteries for some reason, leading to an imbalance between the two key factors, sFlt1 and PIGF, which in turn results in the development of preeclampsia, with the maternal blood pressure become elevated.
An sFlt1/PlGF ratio > 38 is associated with an adverse pregnancy prognosis, irrespective of whether the patient develops clinical preeclampsia. Pregnant women presenting with an elevated sFlt1/PIGF ratio above this threshold have a 2.9-fold increased risk of preterm delivery.
The preterm birth rate is up to 71% higher in pregnant women with an sFlt-1/PlGF ratio exceeding 38, compared to those with a ratio below 38. For those with an elevated sFlt1/PIGF ratio above 38, the median time to delivery is approximately 17 days (causing preterm birth or the development of complications from preeclampsia that require abortion). In contrast, those with an sFlt1/PIGF ratio below 38 have a median time to delivery of 51 days.
Preeclampsia Testing at GENTIS
First Trimester: PlGF index (gestational weeks 11-14) combined with maternal history, clinical examination findings, and ultrasound results.
Second and Third Trimesters: sFLT-1/PIGF ratio to predict adverse pregnancy outcomes in pregnant women.
- Second Trimester: 19 weeks 1 day to 24 weeks 6 days
- Third Trimester: 30 weeks to 37 weeks 6 days
- Sample required: 2 ml peripheral blood
- Turnaround time: 2 days
Preeclampsia is a severe obstetric event that requires close monitoring, as it can lead to numerous hazardous complications for both the mother and the baby. The prevention of complications can occur early if you adhere to comprehensive prenatal care and follow the pregnancy monitoring advice provided by the physician.
The ASRM 2023 Scientific Congress & Expo was held from October 14-18 in New Orleans, Louisiana
ASRM 2023 is the world’s leading and prestigious annual scientific congress organized by the American Society for Reproductive Medicine (ASRM). The 79th annual ASRM Congress attracted approximately 9,000 attendees, including experts from around the globe.
This year's theme for the ASRM Scientific Congress & Expo was “THE PAST, THE PRESENT, THE PIPELINE.” Dr. Ruben Alvero, Professor of Obstetrics and Gynecology at Stanford University and Chair of the Scientific Program, along with Dr. Samantha Butts, Chair of the Postgraduate Program, and their team, designed a comprehensive and engaging program for the conference delegates.
The richness of the program was crafted to address the need for updated knowledge and practical training for doctors, nurses, laboratory staff, embryologists, genetic specialists, and others working in the healthcare field.
At ASRM 2023, multidisciplinary experts explored the latest developments in reproductive endocrinology, infertility, basic science, genetics, male reproduction, access to care, mental health, and more. The conference content was highly appreciated by the delegates.
Representing GENTIS, the delegation was led by Mr. Do Manh Ha – CEO, Mr. Nguyen Quang Vinh – Director of the Testing Center, and Mr. Pham Dinh Minh – Director of R&D.
Mr. Do Manh Ha (CEO of GENTIS), Dr. Michael Thomas – Professor and Chair of Department of Obstetrics & Gynecology at the University of Cincinnati, and Mr. Pham Dinh Minh (Director of R&D, GENTIS) (from left to right)
Notably, the GENTIS representatives had the honor of meeting, networking, and exchanging ideas with Dr. Michael Thomas – Professor and Chair of the Department of Obstetrics & Gynecology at the University of Cincinnati. Dr. Thomas is currently the President of ASRM for 2022-2023. The meeting was highly informative, and the President graciously accepted an invitation to visit GENTIS in Vietnam in the future.
Dr. Michael Thomas – Professor and Chair of Department of Obstetrics & Gynecology at the University of Cincinnati, and Mr. Pham Dinh Minh (Director of R&D, GENTIS)
Once again, GENTIS extends its best wishes for the continued success of the ASRM 2023 Scientific Congress & Expo!
[content_more] => [meta_title] => GENTIS Participated in the ASRM 2023 Scientific Congress & Expo [meta_description] => From October 14 to 18, 2023, the ASRM 2023 Scientific Congress & Expo officially took place in New Orleans, Louisiana. GENTIS was represented at ASRM 2023 by Mr. Do Manh Ha – CEO, Mr. Pham Dinh Minh – Director of R&D, and Mr. Nguyen Quang Vinh – Director [meta_keyword] => ASRM 2023 Scientific Congress & Expo [thumbnail_alt] => [post_id] => 1148 [category_id] => 4 ) [6] => stdClass Object ( [id] => 1147 [id_crawler] => [category_product] => NULL [thumbnail] => 1-pgt.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2023-10-17 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2023-10-17 08:37:18 [updated_time] => 2024-08-19 14:16:14 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 0 [language_code] => en [slug] => preimplantation-genetic-testing-for-monogenic-disorders-pgt-m-and-what-you-need- to-know [title] => Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) and What You Need to Know [description] => In the field of reproductive assistance, selecting an IVF embryo for implantation into the uterus should not solely rely on morphology but also on genetic information obtained through testing. This ensures the selection of high-quality preimplantation embryos and increases the chances of a successful pregnancy. PGT-M is performed on embryos to detect genetic disorders caused by pre-identified gene mutations or clear family history. [content] =>1. What is PGT-M?
PGT-M is a preimplantation genetic screening test for 10 common recessive single-gene disorders. This test helps couples select embryos that do not carry the disease-causing gene mutation, thereby preventing the transmission of genetic disorders to the next generation.
Candidates indicated for PGT-M typically include couples where both partners carry mutations for diseases such as Thalassemia, spinal muscular atrophy, cystic fibrosis, etc. It is also indicated for women carrying X-linked gene mutations (e.g., Hemophilia, Duchenne/Becker muscular dystrophy). Following testing, embryos free of disease-causing genes are selected for transfer into the mother's uterus.
2. Effectiveness of Preimplantation Genetic Testing (PGT-M)
PGT testing has significantly contributed to selecting the healthiest embryos for implantation, increasing the chances of conceptions, reducing miscarriage rates, improving embryo survival rates, decreasing the number of IVF cycles needed to achieve pregnancy, lowering the risk of multiple pregnancies, reducing the incidence of single-gene disorders in offspring, and saving both time and costs associated with IVF.
Moreover, PGT-M testing also identifies abnormalities and single-gene mutations associated with several genetic syndromes such as Thalassemia (including alpha and beta thalassemia), spinal muscular atrophy (SMA), Hemophilia, Rett syndrome, polycystic kidney disease, Duchenne muscular dystrophy, congenital muscular dystrophy, and more. The effectiveness of PGT-M has been clearly demonstrated in reducing the incidence of children born with single-gene disorders and minimizing the need for mid-pregnancy terminations due to abnormal fetuses.
Preimplantation genetic screening and diagnosis for severe genetic disorders are not just personal family matters but are long-term steps involving the contribution of society and the healthcare field. It helps reduce the number of children born with congenital anomalies, serious genetic disorders, and other undesirable abnormalities in couples.
3. How is PGT-M performed at GENTIS?
Currently, PGT-M testing can be performed at hospitals or specialized centers in Vietnam. GENTIS is recognized as a unit capable of performing this technique with precision and professionalism.
At GENTIS, PGT-M testing is conducted using advanced technological techniques, employing modern equipment (such as the Illumina NGS – USA, Veriseq PGS technology) and specialized analysis software (SNP, STR analysis methods). PGT-M is carefully developed and executed to provide highly reliable results.
Combining PGT-M testing for single-gene disorder screening with PGT-A for chromosomal abnormality screening allows couples to select embryos free of genetic abnormalities for transfer into the mother's uterus. With ongoing advancements in technology, GENTIS aims to successfully research and test for other rare genetic disorders, enhancing the success of preimplantation screening and helping infertile couples give birth to healthy babies.
[content_more] => [meta_title] => Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) and What You Need to Know [meta_description] => In the field of reproductive assistance, selecting an IVF embryo for implantation into the uterus should not solely rely on morphology but also on genetic information obtained through testing. This ensures the selection of high-quality preimplantation emb [meta_keyword] => Preimplantation Genetic Testing,PGT-M [thumbnail_alt] => [post_id] => 1147 [category_id] => 4 ) [7] => stdClass Object ( [id] => 1146 [id_crawler] => [category_product] => NULL [thumbnail] => ht-sk_2023/doanh_nhan_tay_ho_13-10-23/doan_nhan_tay_ho_2023_-3.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2023-10-13 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2023-10-13 15:21:51 [updated_time] => 2024-08-28 14:33:56 [files] => [salary] => [time] => [created_by] => 62 [is_table_content] => 0 [language_code] => en [slug] => Tay-ho-district-honors-GENTIS-as-an-exemplary-enterprise-in-2023 [title] => Tay Ho District honors GENTIS as an exemplary enterprise in 2023. [description] => On Vietnam Entrepreneurs' Day (October 13, 2023), a representative from GENTIS attended the Conference to Honor Businesses and Production and Business Establishments in Tay Ho District, held at the headquarters of the District Party Committee - People's Council - People's Committee of Tay Ho District. [content] =>
The conference was attended by representatives at all levels of leadership and more than 90 delegates from enterprises within the district.
Through the first nine months of 2023 report, the district leader acknowledged the contributions of businesses and production establishments to the socio-economic development of the district.
At the ceremony, Mr. Do Van Lap, Financial Director of GENTIS, delivered a speech about the company’s business activities and contributions over the past year.
Mr. Do Van Lap, Financial Director of GENTIS gave a speech at the Conference
"As a law-abiding enterprise, GENTIS consistently adheres to legal regulations and fully recognizes the importance of occupational safety and hygiene in the context of international economic integration.
Therefore, GENTIS places great emphasis on management as well as compliance with regulations regarding public order, environmental hygiene, disease prevention, tax policies, laws, ensuring job creation, income security, and social welfare for employees, thereby contributing to the socio-economic development of Tay Ho District in particular and the country as a whole.
GENTIS is also delighted to have received support and assistance from the Tay Ho District Party Committee, and we hope that there will be more opportunities for businesses to connect and collaborate , which will be created by the district's leader." Mr. Lap shared at the Honoring Conference.
Mr. Do Van Lap's speech received enthusiastic applause from all the delegates and businesses attending the conference. Following GENTIS, other enterprises in the district also delivered lively speeches and presentations to the District Party Committee.
Also at the conference, GENTIS was proud to be one of the 40 businesses in the district recognized and awarded a Certificate of Merit by the Chairman of the People's Committee of Tay Ho District.
Mr. Do Van Lap, representing GENTIS, received the Certificate of Merit from the leaders of Tay Ho District.
GENTIS would like to express our gratitude to the city’s Departments, as well as the District Party Committee, for the ongoing support of the company's activities. Once again, congratulations on the successful conclusion of the 2023 Conference to Honor Businesses and Production and Business Establishments in Tay Ho District.
[content_more] => [meta_title] => Tay Ho District honors GENTIS as an exemplary enterprise in 2023. [meta_description] => A representative from GENTIS attended the Conference to Honor Businesses and Production and Business Establishments in Tay Ho District, [meta_keyword] => GENTIS,honor,ExemplaryEnterprise [thumbnail_alt] => [post_id] => 1146 [category_id] => 4 ) )
GENTIS Sponsored and Presented at the Colloquium on Preimplantation Genetic Testing
GENTIS Proudly Sponsors Pre-implantation Genetic Testing Symposium
GENTIS was recognized as an exemplary taxpaying business in the Capital City for 2022.
GENTIS commemorated 13 Years of Establishment: Promoting the Spirit of UNION FOR BREAKTHROUGH
High-risk individuals and the Etiological Factors of Preeclampsia
GENTIS Participated in the ASRM 2023 Scientific Congress & Expo
Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) and What You Need to Know
Tay Ho District honors GENTIS as an exemplary enterprise in 2023.
Quý khách vui lòng điền thông tin bên dưới để được hỗ trợ,
tư vấn một cách tốt nhất!
Quý khách vui lòng điền thông tin bên dưới để được hỗ trợ,
tư vấn một cách tốt nhất!
